Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13946697 | 0.90 | SMN1; SMN2 (0.56) | HTTSMN1; SMN2LMNAMAPTTP53 | |
| SCHEMBL9514131 | 0.86 | ALDH1A1 (0.60) | HTTSMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL28958322 | 0.83 | ALDH1A1 (0.50) | HTTSMN1; SMN2ALDH1A1POLBKMT2A | |
| SCHEMBL4182979 | 0.82 | MAPK1 (0.57) | SMN1; SMN2LMNAMAPTTP53ALDH1A1 | |
| SCHEMBL28958218 | 0.82 | POLB (0.56) | HTTLMNATP53ALDH1A1POLB | |
| SCHEMBL9512641 | 0.82 | POLB (0.62) | SMN1; SMN2LMNAMAPTALDH1A1POLB | |
| SCHEMBL13946686 | 0.79 | HTT (0.52) | HTTSMN1; SMN2LMNAMAPTTP53 | |
| SCHEMBL9743824 | 0.79 | ALDH1A1 (0.44) | HTTSMN1; SMN2ALDH1A1KMT2ATDP1 | |
| SCHEMBL9741850 | 0.79 | ALDH1A1 (0.49) | HTTALDH1A1POLBKDM4E | |
| SCHEMBL14094206 | 0.79 | ALDH1A1 (0.41) | HTTSMN1; SMN2LMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110294719-B | Synthesis method of thiazolidone compound | 五邑大学 | 2023-02-28 | — | — | CN | disclosed |
| US-20090029964-A1 | Novel carbapenem compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090029964-A1 | Novel carbapenem compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1864985-A1 | NOVEL CARBAPENEM COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-0320910-B1 | 2-Thiazolidinone derivatives, pharmaceutical compositions containing them, process for preparing same, and use | RICHTER GEDEON VEGYESZET (HU) | 1993-12-08 | — | — | EP | disclosed |
| US-4937252-A | 2-thiazolidinone derivatives, pharmaceutical compositions containing them and process for preparing same | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1990-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029964-A1 | Novel carbapenem compound | MGAM2, OXA1L, RIOX2 | HTT 4849/4885SMN1; SMN2 458/4885LMNA 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.